ClinicalTrials.gg
CompletedNCT01002079Updated Jan 25, 2011

Drug-Drug Interaction Study With Rifampin

A Phase 1 interventional study of BMS-708163 and Rifampin in Alzheimer Disease, sponsored by Bristol-Myers Squibb. Completed at 1 site in India. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-01-25.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing BMS 708163 in Alzheimer Disease — none open to participants now, none under way, none of them phase 3. BMS 708163 · Alzheimer Disease.

Enrollment
10th of 12
20 · median 31
Started
2010
with 4 others
Phase 1
10 of 12
none open now
Registered
7th of 12
by date
Lead sponsor
12 of 12
Bristol-Myers Squibb

Among the 12 studies testing BMS 708163 in Alzheimer Disease, this one is the 10th largest by enrollment, is one of 5 that started in 2010, is one of 10 in phase 1, and was the 7th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

None of the 12 studies testing BMS 708163 in Alzheimer Disease is open now. The open studies under Alzheimer Disease, anywhere →

About BMS 708163

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing BMS 708163 in Alzheimer Disease as a file.
02

Study summary

The purpose of the study is to determine if the concomitant administration of rifampin with BMS-708163 will affect the Pharmacokinetics of BMS-708163 and to assess safety and tolerability of co-administration BMS-708163 and rifampin

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female subjects, 18-55 yrs old inclusive

Exclusion criteria

Exclusion Criteria:

  • Women of
  • Tuberculosis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    BMS-708163

    Drug: BMS-708163

  • Other
    Rifampin

    Drug: Rifampin

  • Experimental
    Rifampin + BMS-708163

    Drug: BMS-708163 · Drug: Rifampin

Interventions

  • Capsule, Oral, 125 mg, Once daily, 1 day

  • Capsule, Oral, 600 mg, Once daily, 7 days

  • Capsule, Oral, 600 mg, Once daily, 6 days

06

What researchers measure

Primary outcomes

  1. BMS-708163 alone and with rifampin: BMS-708163 single dose PK parameters (Cmax, Tmax, T-HALF, AUC(0-T), AUC(INF), CLT/F and molar AUCmet/AUCparent ratios will be assessed without rifampin (Day 1) and with rifampin (Day 13)

    Time frame: Within 30 days after dose

Secondary outcomes

  1. BMS-708163 alone and with rifampin: Safety and tolerability (AE's, ECG, vital signs, safety labs)

    Time frame: Within 30 days after dose

07

Study locations

1 site
  • Local Institution
    Bangalore, 560100, India
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2009
First posted
Oct 27, 2009
Start
Aug 2010
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Last update
Jan 25, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01002079
Collaborators
PRA Health Sciences
First posted
Oct 27, 2009
Start date
Aug 2010
Primary completion
Oct 2010
Completion
Oct 2010
Last update
Jan 25, 2011

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BMS 708163 · Rifampin

Start the discussion